BR9917082A - Compostos inibidores da produção de proteìnas a"beta", método de tratamento de disfunções neurológicas associadas com a produção de "beta"-amilóide, composição farmacêutica e, método de inibição da atividade de y-secretase - Google Patents

Compostos inibidores da produção de proteìnas a"beta", método de tratamento de disfunções neurológicas associadas com a produção de "beta"-amilóide, composição farmacêutica e, método de inibição da atividade de y-secretase

Info

Publication number
BR9917082A
BR9917082A BR9917082-5A BR9917082A BR9917082A BR 9917082 A BR9917082 A BR 9917082A BR 9917082 A BR9917082 A BR 9917082A BR 9917082 A BR9917082 A BR 9917082A
Authority
BR
Brazil
Prior art keywords
production
beta
amyloid
inhibit
compounds
Prior art date
Application number
BR9917082-5A
Other languages
English (en)
Inventor
Richard E Olson
Original Assignee
Du Pont Pharm Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Du Pont Pharm Co filed Critical Du Pont Pharm Co
Publication of BR9917082A publication Critical patent/BR9917082A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/12—1,5-Benzodiazepines; Hydrogenated 1,5-benzodiazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"COMPOSTOS INIBIDORES DA PRODUçãO DE PROTEìNAS A<225>, MéTODO DE TRATAMENTO DE DISFUNçõES NEUROLóGICAS ASSOCIADAS COM A PRODUçãO DE <225>-AMILóIDE, COMPOSIçãO FARMACêUTICA E, MéTODO DE INIBIçãO DA ATIVIDADE DE <sym>-SECRETASE". A presente invenção refere-se a lactamas inovadoras que possuem a fórmula (I), suas composições farmacêuticas e seus métodos de utilização. Esses compostos inovadores inibem o processamento da proteína precursora de amilóide e, mais especificamente, inibem a produção de peptídeo A<225>,de forma a agir na prevenção da formação de depósitos neurológicos de proteínas amilóides. Mais especificamente, a presente invenção refere-se ao tratamento de disfunções neurológicas relacionadas com a produção de,<225>-amilóide, tais como o mal de Aklzheimer e a síndrome de Down.
BR9917082-5A 1998-12-24 1999-12-23 Compostos inibidores da produção de proteìnas a"beta", método de tratamento de disfunções neurológicas associadas com a produção de "beta"-amilóide, composição farmacêutica e, método de inibição da atividade de y-secretase BR9917082A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11358898P 1998-12-24 1998-12-24
PCT/US1999/030815 WO2000038618A2 (en) 1998-12-24 1999-12-23 SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF Aβ PROTEIN PRODUCTION

Publications (1)

Publication Number Publication Date
BR9917082A true BR9917082A (pt) 2001-11-06

Family

ID=22350336

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9917082-5A BR9917082A (pt) 1998-12-24 1999-12-23 Compostos inibidores da produção de proteìnas a"beta", método de tratamento de disfunções neurológicas associadas com a produção de "beta"-amilóide, composição farmacêutica e, método de inibição da atividade de y-secretase

Country Status (10)

Country Link
US (6) US7053084B1 (pt)
EP (1) EP1313426A4 (pt)
JP (1) JP4615727B2 (pt)
CN (1) CN1636011A (pt)
AU (1) AU778005B2 (pt)
BR (1) BR9917082A (pt)
CA (1) CA2347671A1 (pt)
IL (1) IL142816A0 (pt)
NO (1) NO20012984L (pt)
WO (1) WO2000038618A2 (pt)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ525513A (en) 1998-08-07 2004-09-24 Pont Pharmaceuticals Du Succinoylamino lactams as inhibitors of Abeta protein production
CN1636011A (zh) 1998-12-24 2005-07-06 杜邦药品公司 作为Aβ蛋白产生抑制剂的琥珀酰氨基苯并二氮杂䓬
US6503902B2 (en) 1999-09-13 2003-01-07 Bristol-Myers Squibb Pharma Company Hydroxyalkanoylaminolactams and related structures as inhibitors of a β protein production
EP1212306A2 (en) 1999-09-13 2002-06-12 Bristol-Myers Squibb Company Hydroxyalkanoylaminolactams and related structures as inhibitors of abeta protein production
US6960576B2 (en) 1999-09-13 2005-11-01 Bristol-Myers Squibb Pharma Company Hydroxyalkanoylaminolactams and related structures as inhibitors of Aβ protein production
AU7997600A (en) 1999-10-08 2001-04-23 Du Pont Pharmaceuticals Company Amino lactam sulfonamides as inhibitors of abeta protein production
JP2003523345A (ja) * 2000-02-17 2003-08-05 ブリストル−マイヤーズ スクイブ ファーマ カンパニー Ａβタンパク質産生の阻害剤としてのスクシノイルアミノ炭素環および複素環
EP1268434A1 (en) 2000-04-03 2003-01-02 Bristol-Myers Squibb Pharma Company Cyclic lactams as inhibitors of a-beta protein production
CA2404273A1 (en) 2000-04-11 2001-10-18 Bristol-Myers Squibb Pharma Company Substituted lactams as inhibitors of a.beta. protein production
US6878363B2 (en) 2000-05-17 2005-04-12 Bristol-Myers Squibb Pharma Company Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging
GB0012671D0 (en) 2000-05-24 2000-07-19 Merck Sharp & Dohme Therapeutic agents
IL147629A0 (en) 2000-06-01 2002-08-14 Bristol Myers Squibb Pharma Co LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Aβ PROTEIN PRODUCTION
GB0025173D0 (en) * 2000-10-13 2000-11-29 Merck Sharp & Dohme Therapeutic agents
DE10101430B4 (de) * 2001-01-13 2008-10-02 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Lösliche cyclische Analoga zur Modulation der Amyloidogenese
US20030051728A1 (en) 2001-06-05 2003-03-20 Lloyd Peter M. Method and device for delivering a physiologically active compound
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US6974829B2 (en) 2002-05-07 2005-12-13 Elan Pharmaceuticals, Inc. Succinoyl aminopyrazoles and related compounds
US7001901B2 (en) 2002-08-27 2006-02-21 Bristol-Myers Squibb Company Tetrazolylpropionamides as inhibitors of Aβ protein production
TW200502221A (en) * 2002-10-03 2005-01-16 Astrazeneca Ab Novel lactams and uses thereof
ATE441417T1 (de) 2002-12-20 2009-09-15 Glaxo Group Ltd Benzoädüazepinderivate für die behandlung von neurologischen krankheiten
WO2004104493A2 (en) 2003-05-21 2004-12-02 Alexza Pharmaceuticals, Inc. Methods of controlling uniformity of substrate temperature and self-contained heating unit and drug-supply unit employing same
EP2511267A1 (en) 2003-06-05 2012-10-17 Elan Pharmaceuticals Inc. 3-((n-acylated aminoacyl)amino)pyrazoles as inhibitors of beta-amyloid peptide production useful for the treatment of alzheimer's disease
AU2004283803B2 (en) 2003-10-06 2010-06-24 F. Hoffmann-La Roche Ag Substituted dibenzo-azepine and benzo-diazepine derivatives useful as gamma-secretase inhibitors
KR101594898B1 (ko) 2005-07-15 2016-02-18 알바니 몰레큘라 리써치, 인크. 아릴- 및 헤테로아릴-치환된 테트라히드로벤자제핀, 및 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 용도
RU2309944C1 (ru) * 2006-04-12 2007-11-10 Общество с ограниченной ответственностью "ИФОХИМ" Производные пара-метоксианилинов, повышающие стойкость углеводородных топлив к детонации, и топливная композиция (варианты)
JP2010518064A (ja) 2007-02-12 2010-05-27 メルク・シャープ・エンド・ドーム・コーポレイション Ａｄおよび関連状態の治療のためのピペラジン誘導体
US20080216828A1 (en) 2007-03-09 2008-09-11 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
KR20100017766A (ko) 2007-05-10 2010-02-16 에이엠알 테크놀로지, 인크. 아릴- 및 헤테로아릴-치환된 테트라히드로벤조-1,4-디아제핀 및 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 이의 용도
BRPI0821090B8 (pt) 2007-12-21 2021-05-25 Ligand Pharm Inc moduladores seletivos de receptores de androgênio (sarms) e uso do mesmo
US8461389B2 (en) 2008-04-18 2013-06-11 University College Dublin, National University Of Ireland, Dublin Psycho-pharmaceuticals
TWI530489B (zh) 2011-03-22 2016-04-21 必治妥美雅史谷比公司 雙（氟烷基）－１，４－苯二氮呯酮化合物
US9427442B2 (en) 2012-09-21 2016-08-30 Bristol-Myers Squibb Company Fluoroalkyl and fluorocycloalkyl 1,4-benzodiazepinone compounds
US9242941B2 (en) 2012-09-21 2016-01-26 Bristol-Myers Squibb Company Alkyl, fluoroalkyl-1,4-benzodiazepinone compounds
CN104797584A (zh) 2012-09-21 2015-07-22 百时美施贵宝公司 作为notch抑制剂的三环杂环化合物
EP2897944B1 (en) 2012-09-21 2016-10-26 Bristol-Myers Squibb Company Substituted 1,5-benzodiazepinone compounds
WO2014047393A1 (en) * 2012-09-21 2014-03-27 Bristol-Myers Squibb Company N-substituted bis(fluoroalkyl)-1,4-benzodiazepinone compounds as notch inhibitors
JP2015529250A (ja) * 2012-09-21 2015-10-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ フルオロアルキルジベンゾジアゼピノン化合物
EP2897941B1 (en) 2012-09-21 2016-09-07 Bristol-Myers Squibb Company Prodrugs of 1,4-benzodiazepinone compounds
TWI614238B (zh) * 2012-09-21 2018-02-11 必治妥美雅史谷比公司 雙（氟烷基）－１，４－苯并二氮呯酮化合物及其前藥
WO2014047392A1 (en) 2012-09-21 2014-03-27 Bristol-Myers Squibb Company Fluoroalkyl-1,4-benzodiazepinone compounds
CN105101968A (zh) 2013-04-04 2015-11-25 百时美施贵宝公司 治疗增殖性疾病的组合疗法
EP3094323A4 (en) 2014-01-17 2017-10-11 Ligand Pharmaceuticals Incorporated Methods and compositions for modulating hormone levels
WO2019099532A1 (en) * 2017-11-14 2019-05-23 Northwestern University Treatment of sleep-wake disorders and neurodegenerative disease comprising modified resistant maltodextrin
AU2019275284A1 (en) * 2018-05-24 2021-01-14 Ayala Pharmaceuticals Inc. Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and immunotherapeutics and methods of use thereof
CA3227665A1 (en) 2021-08-02 2023-02-09 Wassilios Grammenos (3-pirydyl)-quinazoline
AU2022323668A1 (en) 2021-08-02 2024-02-15 Basf Se (3-quinolyl)-quinazoline
WO2024104815A1 (en) 2022-11-16 2024-05-23 Basf Se Substituted benzodiazepines as fungicides
WO2024104818A1 (en) 2022-11-16 2024-05-23 Basf Se Substituted benzodiazepines as fungicides
WO2024104822A1 (en) 2022-11-16 2024-05-23 Basf Se Substituted tetrahydrobenzodiazepine as fungicides

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3651023A (en) * 1968-07-02 1972-03-21 Stamicarbon Preparation of polyamides with special properties
FR2630440B1 (fr) 1988-04-25 1991-09-20 Jouveinal Sa Benzodiazepines, leur procede et intermediaires de preparation et leurs applications en therapeutique
DK0411668T4 (da) 1989-08-04 1999-08-09 Merck Sharp & Dohme Central-chlolecystokinin-antagonister til behandling af psykiske forstyrrelser
CA2026856A1 (en) 1989-10-05 1991-04-06 Mark G. Bock 3-substituted-1,4-benzodiazepines useful as oxytocin
CA2032427A1 (en) 1989-12-18 1991-06-19 Mark G. Bock Benzodiazepines analogs
GB9107368D0 (en) 1991-04-08 1991-05-22 Smithkline Beecham Plc Novel compounds
FR2681962B1 (fr) * 1991-09-30 1993-12-24 Sgs Thomson Microelectronics Sa Procede et circuit de traitement de donnees par transformee cosinus.
EP0652871B1 (en) 1992-07-29 2001-10-17 MERCK SHARP &amp; DOHME LTD. Benzodiazepine derivatives
US5283241A (en) 1992-08-28 1994-02-01 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
AU689762B2 (en) 1992-12-21 1998-04-09 Smithkline Beecham Corporation Bicyclic fibrinogen antagonists
MX9308016A (es) 1992-12-22 1994-08-31 Lilly Co Eli Compuestos inhibidores de la proteasa del virus de la inmunodeficiencia humana, procedimiento para su preparacion y formulacion farmaceutica que los contiene.
EP0763537A3 (en) 1993-05-14 1997-10-22 Genentech Inc Non-peptides farnesyl transfer inhibitors
EP0702671A4 (en) 1993-06-09 1996-06-19 Smithkline Beecham Corp BICYCLIC FIBRINOGEN ANTAGONISTS
US5602156A (en) 1993-09-17 1997-02-11 The United States Of America As Represented By The Department Of Health And Human Services Method for inhibiting metalloproteinase expression
US5545735A (en) 1993-10-04 1996-08-13 Merck & Co., Inc. Benzo-Fused Lactams promote release of growth hormone
US5332359A (en) * 1993-10-12 1994-07-26 United Technologies Corporation Stator assembly for a rotary machine having a centrifugal on impeller and volute
US5426185A (en) 1993-11-22 1995-06-20 Merck & Co., Inc. Antiarrhythmic benzodiazepines
US5770573A (en) 1993-12-06 1998-06-23 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
WO1996004254A2 (en) 1994-07-29 1996-02-15 Fujisawa Pharmaceutical Co., Ltd. Benzodiazepine derivatives
US5661161A (en) 1994-09-29 1997-08-26 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO1996017833A1 (en) 1994-12-09 1996-06-13 Smithkline Beecham Corporation Bicyclic fibrinogen antagonists
US6117910A (en) 1994-12-13 2000-09-12 Smithkline Beecham Corporation Bicyclic fibrinogen antagonists
US5639746A (en) 1994-12-29 1997-06-17 The Procter & Gamble Company Hydroxamic acid-containing inhibitors of matrix metalloproteases
US5672598A (en) * 1995-03-21 1997-09-30 The Procter & Gamble Company Lactam-containing hydroxamic acids
US5856326A (en) 1995-03-29 1999-01-05 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5578629A (en) 1995-03-29 1996-11-26 Merck & Co., Inc. Benzamide-containing inhibitors of farnesyl-protein transferase
GB9507799D0 (en) 1995-04-18 1995-05-31 British Biotech Pharm Metalloproteinase inhibitors
US5710171A (en) 1995-05-24 1998-01-20 Merck & Co., Inc. Bisphenyl inhibitors of farnesyl-protein transferase
ATE288444T1 (de) 1995-05-29 2005-02-15 Pfizer Dipeptide, die die ausschüttung von wachstumshormonen stimulieren
US5756528A (en) 1995-06-06 1998-05-26 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO1997009066A1 (fr) * 1995-09-08 1997-03-13 Kanebo, Ltd. INHIBITEUR DE SOLUBILISATION DE LIGAND Fas
JPH09188631A (ja) * 1995-09-08 1997-07-22 Kanebo Ltd Ｆａｓリガンド可溶化抑制薬
EP0761680A3 (en) 1995-09-12 1999-05-06 Ono Pharmaceutical Co., Ltd. Tetrazole compounds having Interleukin-1beta converting enzyme inhibitory activity
WO1997012861A1 (en) 1995-10-05 1997-04-10 Chiroscience Limited Mercaptoamide derivatives and their therapeutic use
US6127427A (en) 1995-11-23 2000-10-03 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
WO1997027852A1 (en) 1996-01-30 1997-08-07 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
JP2000507585A (ja) 1996-04-03 2000-06-20 メルク エンド カンパニー インコーポレーテッド ファルネシルタンパク質トランスフェラーゼの阻害剤
US5869682A (en) 1996-04-03 1999-02-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO1997036879A1 (en) 1996-04-03 1997-10-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5859012A (en) 1996-04-03 1999-01-12 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5852010A (en) 1996-04-03 1998-12-22 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5965578A (en) 1996-04-03 1999-10-12 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5885995A (en) 1996-04-03 1999-03-23 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
EP0891335A4 (en) 1996-04-03 2001-08-16 Merck & Co Inc FARNESYL-PROTEIN TRANSFERASE INHIBITORS
US5919785A (en) 1996-04-03 1999-07-06 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5891889A (en) 1996-04-03 1999-04-06 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
EP0952842A2 (en) 1996-04-18 1999-11-03 Merck & Co., Inc. A method of treating cancer
JP2000508335A (ja) 1996-05-30 2000-07-04 メルク エンド カンパニー インコーポレーテッド 癌の治療方法
US5703129A (en) 1996-09-30 1997-12-30 Bristol-Myers Squibb Company 5-amino-6-cyclohexyl-4-hydroxy-hexanamide derivatives as inhibitors of β-amyloid protein production
CA2268281A1 (en) 1996-10-11 1998-04-23 Cor Therapeutics, Inc. Selective factor xa inhibitors
DE19647382A1 (de) 1996-11-15 1998-05-20 Hoechst Ag Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
ID22275A (id) 1996-11-22 1999-09-23 Elan Pharm Inc Komposisi farmasi yang terdiri dari derivat asam amino n-(aril atau heteroaril) dan metode untuk menghambat pelepasan b-amiloid peptida dan atau sintesisnya dengan menggunakan senyawa tersebut
KR20000069075A (ko) 1996-11-22 2000-11-25 진 엠. 듀발 Ｎ-(아릴/헤테로아릴/알킬아세틸)아미노산 아미드, 이들을 함유하는 제약 조성물, 및 이들 화합물을 사용하여 베타-아밀로이드 펩티드의 방출 및(또는) 합성의 억제 방법
HUP0000492A3 (en) 1996-11-22 2000-06-28 Lilly Co Eli N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
WO1998022441A2 (en) 1996-11-22 1998-05-28 Elan Pharmaceuticals, Inc. N-(aryl/heteroaryl) amino acid esters, pharmaceutical compositions, and methods for inhibiting beta-amyloid peptide and/or its synthesis
TW523506B (en) 1996-12-18 2003-03-11 Ono Pharmaceutical Co Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients
TR199901343T2 (xx) * 1996-12-23 1999-09-21 Elan Pharmaceuticals, Inc. Sikloalkil, laktam, lakton ve ilgili bile�ikler, bunlar� i�eren farmas�tik bile�imler ve b�yle bile�ikler kullan�larak �-amiloid peptidinin sal�nmas�n� ve/veya sentezini inhibe etmek i�in y�ntemler.
AU6013998A (en) 1996-12-30 1998-07-31 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
JP2002241368A (ja) * 1997-02-18 2002-08-28 Shionogi & Co Ltd 新規ベンゾラクタム誘導体およびそれを含有する医薬組成物
EP0968206B8 (en) 1997-02-19 2007-01-24 Berlex, Inc. N-heterocyclic derivatives as nos inhibitors
WO1998041510A1 (fr) 1997-03-14 1998-09-24 Shionogi & Co., Ltd. Nouveaux derives du benzolactame et compositions medicamenteuses les contenant
US5985900A (en) 1997-04-01 1999-11-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
JP2001524079A (ja) 1997-04-07 2001-11-27 メルク エンド カンパニー インコーポレーテッド ガンの治療方法
DE19717472A1 (de) 1997-04-25 1998-10-29 Suban Ag Verfahren und Vorrichtung zum Profilbiegen mit modularen Biegestationen
US6060038A (en) 1997-05-15 2000-05-09 Merck & Co., Inc. Radiolabeled farnesyl-protein transferase inhibitors
DE19726427A1 (de) 1997-06-23 1998-12-24 Boehringer Mannheim Gmbh Pyrimidin-2,4,6-trion-Derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
GB9715030D0 (en) 1997-07-18 1997-09-24 British Biotech Pharm Metalloproteinase inhibitors
JP2001515842A (ja) 1997-08-11 2001-09-25 シーオーアール セラピューティクス インコーポレイテッド 選択的Ｘａ因子阻害剤
NZ502803A (en) 1997-08-11 2001-11-30 Cor Therapeutics Inc Selective factor Xa inhibitors for treating diseases such as angina, myocardial infarction, transient ischemic attacks or diseases associated with undesired thrombosis
WO1999018951A1 (en) 1997-09-29 1999-04-22 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
US6297239B1 (en) 1997-10-08 2001-10-02 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6440965B1 (en) 1997-10-15 2002-08-27 Krenitsky Pharmaceuticals, Inc. Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
IL135564A0 (en) 1997-12-22 2001-05-20 Elan Pharm Inc POLYCYCLIC α-AMINO-ɛ-CAPROLACTAMS AND RELATED COMPOUNDS
EP1057070B1 (en) 1998-02-20 2011-03-02 PureDepth Limited A multi-layer display and a method for displaying images on such a display
JP2002518451A (ja) 1998-06-22 2002-06-25 エラン ファーマシューティカルズ，インコーポレイテッド 環状アミノ酸化合物およびその医薬組成物、並びにそれら化合物を用いたβ−アミロイドペプチドの放出および／またはその合成を阻害する方法
CA2324474A1 (en) 1998-06-22 1999-12-29 Elan Pharmaceuticals, Inc. Compounds for inhibiting beta-amyloid peptide release and/or its synthesis
CA2325388A1 (en) 1998-06-22 1999-12-29 Elan Pharmaceuticals, Inc. Compounds for inhibiting beta-amyloid peptide release and/or its synthesis
EP1089980A1 (en) 1998-06-22 2001-04-11 Elan Pharmaceuticals, Inc. Compounds for inhibiting beta-amyloid peptide release and/or its synthesis
AU1915399A (en) 1998-07-10 2000-02-01 Cytel Corporation Cs-1 peptidomimetics, compositions and methods of using the same
NZ525513A (en) * 1998-08-07 2004-09-24 Pont Pharmaceuticals Du Succinoylamino lactams as inhibitors of Abeta protein production
HRP990246A2 (en) * 1998-08-07 2000-06-30 Du Pont Pharm Co Succinoylamino benzodiazepines as inhibitors of a beta protein production
CA2346099A1 (en) * 1998-11-12 2000-05-18 Dupont Pharmaceuticals Company Use of radioligands to screen inhibitors of amyloid-beta peptide production
CN1636011A (zh) 1998-12-24 2005-07-06 杜邦药品公司 作为Aβ蛋白产生抑制剂的琥珀酰氨基苯并二氮杂䓬
JP2003523345A (ja) 2000-02-17 2003-08-05 ブリストル−マイヤーズ スクイブ ファーマ カンパニー Ａβタンパク質産生の阻害剤としてのスクシノイルアミノ炭素環および複素環
IL147629A0 (en) * 2000-06-01 2002-08-14 Bristol Myers Squibb Pharma Co LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Aβ PROTEIN PRODUCTION
CA2674915C (en) 2006-10-17 2015-06-30 Penick Corporation Process for preparing oxymorphone

Also Published As

Publication number Publication date
US20080171735A1 (en) 2008-07-17
US7053084B1 (en) 2006-05-30
US7456172B2 (en) 2008-11-25
EP1313426A2 (en) 2003-05-28
CN1636011A (zh) 2005-07-06
US7304049B2 (en) 2007-12-04
IL142816A0 (en) 2002-03-10
JP4615727B2 (ja) 2011-01-19
EP1313426A4 (en) 2003-05-28
JP2003523932A (ja) 2003-08-12
US20080207602A1 (en) 2008-08-28
US7718795B2 (en) 2010-05-18
US20060122169A1 (en) 2006-06-08
AU778005B2 (en) 2004-11-11
WO2000038618A2 (en) 2000-07-06
NO20012984D0 (no) 2001-06-15
CA2347671A1 (en) 2000-07-06
US20090069293A1 (en) 2009-03-12
AU2059200A (en) 2000-07-31
US20060025407A1 (en) 2006-02-02
WO2000038618A3 (en) 2003-04-03
NO20012984L (no) 2001-06-15

Similar Documents

Publication Publication Date Title
BR9917082A (pt) Compostos inibidores da produção de proteìnas a&#34;beta&#34;, método de tratamento de disfunções neurológicas associadas com a produção de &#34;beta&#34;-amilóide, composição farmacêutica e, método de inibição da atividade de y-secretase
BR0106717A (pt) Compostos, composição farmacêutica e usos dos compostos de lactama inovadora
BR0107532A (pt) Composto, uso do composto, método para o tratamento de disfunções neurológicas associadas com a produção de b-amilóide, método de inibição da atividade de y-secretase e composição farmacêutica
BR9912969A (pt) Composto, composição farmacêutica, método para o tratamento dos distúrbios neurológicos associados com a produção de b-amilóide, método para o tratamento da doença de alzheimer associada com a produção de b-amilóide, método para o tratamento dos distúrbios neurológicos associados com a produção de b-amilóide e método para inibir a atividade de y-secretase
BR0110051A (pt) Composto, uso do composto, composição farmacêutica e método de tratamento do mal de alzheimer
DE69429527D1 (de) Inhibitoren von beta-amyloid-protein-herstellung
ES2137948T3 (es) Sistema avanzado de administracion de medicamentos y metodo de tratamiento de trastornos psiquiatricos, neurologicos y otros con carbamacepina.
BR9611210A (pt) Composições e processos para tratamento de condições ósseas deficitárias
BR9913319A (pt) Composições e métodos para tratamento de doenças mitocondriais
BR0014269A (pt) Compostos de lactamas, seus sais e pró-drogas farmaceuticamente aceitáveis, composição farmacêutica, método de tratamento de disfunções neurológicas associadas com a produção de &#34;beta&#34;-amilóide, método de inibição da atividade da &#34;alfa&#34;-secretase e usos dos compostos
BR9709959A (pt) Derivados tricìclicos de fenilamino substituìdo para o tratamento de doenças hiperproliferativas
ATE374029T1 (de) Behandlung der alzheimer-krankheit durch erhöhung des cytidin-spiegels in vivo
IT1254915B (it) Derivati di adenosina ad attivita&#39; a2 agonista
EA199901014A1 (ru) C-4&#34;-замещенные макролидные производные
MA26435A1 (fr) Derives de benzylamine amido-substitues, leurs derives precurseurs de medicaments, leur procede de preparation, compositions pharmaceutiques les contenant et methode de traitement les utilisant.
BR9900856A (pt) Antibioticos macrolideos de 3,6-cetal e enol-éter
ATE82681T1 (de) 2&#39;,3&#39;-dideoxy-3&#39;-fluorothymidin und verwandte verbindungen zur behandlung von adenovirusinfektionen.
BR9812577A (pt) Composto, processo para preparar o mesmo, composição farmacêutica, e, processo para tratar infecções bacterianas
FI101377B1 (fi) Menetelmä N-alkyloitujen 1,4-dihydropyridiiniyhdisteiden valmistamiseksi
WO1996022305A3 (en) Modified peptides
BR0316039A (pt) Precursor de n-acetilgalactosamina-4-sulfatase, métodos de tratamento usando a enzima e métodos para produção e purificação da enzima
DE60108130D1 (de) Pharmazeutische zusammensetzungen zur behandlung von neurologischen krankheiten
DE69926794D1 (de) Ponazuril zur behandlung von durch coccidia neurologischen und &#34;abortigenic&#34; verursachten erkrankungen
KR960000248A (ko) 골대사 질환 치료제
RU93036929A (ru) Способ очистки препарата гадолиния-153 от европия-152

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6O E 7O ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1913 DE 04/09/2007.